Chronic Stress May Drive Lymph Node Metastasis in Postmenopausal Endometrial Cancer, Study Finds

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-01-26 15:45 GMT   |   Update On 2025-01-26 15:45 GMT

South Korea: A study published on November 18 in Scientific Reports suggests that brain activity linked to chronic stress may influence the aggressiveness of tumors in women with endometrial cancer. Using PET imaging, researchers analyzed 161 women and found that high amygdala activity (AmygA) was associated with lymph node (LN) metastasis in postmenopausal patients but not in premenopausal patients.

Lead authors Ki-Jin Ryu, MD, PhD, and Sungeun Kim, MD, PhD, from the Korea University College of Medicine in Seoul, highlighted that the study provides new insights into the connection between chronic stress, as indicated by AmygA, and LN metastasis in endometrial cancer patients, particularly in postmenopausal women.

While numerous studies have shown that chronic stress can increase the risk and aggressiveness of tumors in cancers like stomach, lung, and skin cancer, the connection between chronic stress and endometrial cancer remains unclear. To further explore connections, the researchers aimed to investigate the relationship between AmygA and lymph node metastasis in patients with endometrial cancer.

For this purpose, the researchers recruited a total of 161 patients with newly diagnosed endometrial cancer who underwent preoperative 18F-FDG PET/CT scans. AmygA was calculated by dividing the maximum standardized uptake value (SUVmax) of the amygdala by the mean standardized uptake value (SUVmean) of the temporal lobe.

The study led to the following findings:

  • Postmenopausal patients with positive LN metastasis showed elevated AmygA levels and increased systemic inflammation markers, such as spleen and bone marrow SUVmax, compared to those without LN metastasis.
  • AmygA was independently associated with LN metastasis in postmenopausal patients but not in premenopausal patients.
  • The correlation between AmygA and systemic inflammation markers was more pronounced in postmenopausal patients.

"The lack of a significant link between AmygA and LN metastasis in premenopausal women suggests that menopausal status may influence how stress-related neural activity affects cancer progression," the researchers noted.

While further studies are needed to understand the underlying mechanisms, the findings emphasize the importance of considering menopausal status when assessing stress's impact on cancer progression.

The researchers also suggested that AmygA could be a useful imaging biomarker for identifying patients at higher risk of LN metastasis, particularly in postmenopausal women.

This study has several limitations, including its single-center design, small sample size, and cross-sectional nature, which may introduce bias. The unbalanced lymph node metastasis in premenopausal patients could affect results. The limited resolution of 18F-FDG PET/CT restricted the assessment of stress-related brain regions, and a whole-body scan protocol prevented a more detailed amygdala analysis. Additionally, the researchers couldn't directly evaluate markers of the HPA axis and sympathetic nervous system activity.

Reference:

Ryu, K., Kim, S., Joung, C., Lee, S., Park, H., Song, J. Y., Pahk, K. J., & Pahk, K. (2024). Association between chronic stress-related amygdala metabolic activity and lymph node metastasis in endometrial cancer. Scientific Reports, 14(1), 1-11. https://doi.org/10.1038/s41598-024-79987-8


Tags:    
Article Source : Scientific Reports

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News